Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET
Company Participants
Gayathri Diwakar - Head of Investor Relations
Scott Struthers - Founder and Chief Executive Officer
Dana Pizzuti - Chief Medical and Development Officer
Jim Hassard - Chief Commercial Officer
Marc Wilson - Chief Financial Officer
Alan Krasner - Chief Endocrinologist
Conference Call Participants
Jessica Fye - JPMorgan
Yasmeen Rahimi - Piper Sandler
Jeff Hung - Morgan Stanley
Dennis Ding - Jefferies
Joseph Schwartz - Leerink Partners
Gavin Clark-Gartner - Evercore ISI
Charles Moore - Baird
Catherine Novack - Jones Research
Jon Wolleben - Citizens JMP
Leland Gershell - Oppenheimer
Douglas Tsao - H.C. Wainwright
Cory Jubinville - LifeSci Capital
Operator
Good day everyone, and welcome to the Crinetics Pharmaceuticals Second Quarter 2024 Earnings Conference Call. [Operator Instructions]. Please note this call may be recorded. [Operator Instructions].
It is now my pleasure to turn the program over to Gayathri Diwakar.
Gayathri Diwakar
Thank you, operator. Hello everyone and welcome to Crinetics earning call. Joining me today are Dr. Scott Struthers, Founder and Chief Executive Officer; Dr. Dana Pizzuti, Chief Medical and Development Officer; Jim Hassard, Chief Commercial Officer; and Marc Wilson, Chief Financial Officer; also joining us for the Q&A portion of the call is Dr. Alan Krasner, Chief Endocrinologist.
A press release announcing the first quarter 2024 financial results was issued today and is also available on our corporate website. We'll be using slides for today's presentation, which can be viewed on the Investor Relations section of the Crinetics’ website.
As a reminder, we'll be making forward looking statements and I invite you to learn about the risks and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release, the company's other news releases and Crinetics SEC filing, including its annual report on Form 10-K.
I would also like to specify that the content of this conference call contains time sensitive information that's accurate only as of the date of this live broadcast August 8th, 2024. Crinetics take no obligation to revise or update any forward listen statements to reflect events or circumstances after the date of this conference call.